Namodenoson Explained
| Legal Status: | Investigational |
| Synonyms: | Chloro-IB-MECA; 2-Cl-IB-MECA |
| Cas Number: | 163042-96-4 |
| Pubchem: | 3035850 |
| Unii: | Z07JR07J6C |
| Drugbank: | DB12885 |
| Iuphar Ligand: | 457 |
| Chembl: | 431733 |
| Chemspiderid: | 2299989 |
| Kegg: | D11128 |
| Iupac Name: | (2S,3S,4R,5R)-5-[2-Chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide |
| Stdinchi: | 1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1 |
| Stdinchikey: | IPSYPUKKXMNCNQ-PFHKOEEOSA-N |
| Smiles: | CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O |
| C: | 18 |
| H: | 18 |
| Cl: | 1 |
| I: | 1 |
| N: | 6 |
| O: | 4 |
Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is developed by Can-Fite for non-alcoholic fatty liver disease,[1] liver cancer,[2] and pancreatic cancer.[3]
Notes and References
- Safadi . Rifaat . Braun . Marius . Francis . Adi . Milgrom . Yael . Massarwa . Muhammad . Hakimian . David . Hazou . Wadi . Issachar . Assaf . Harpaz . Zivit . Farbstein . Motti . Itzhak . Inbal . Lev-Cohain . Naama . Bareket-Samish . Avital . Silverman . Michael H. . Fishman . Pnina . Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis . Alimentary Pharmacology & Therapeutics . December 2021 . 54 . 11–12 . 1405–1415 . 10.1111/apt.16664 . 34671996 . 9298378 . 1365-2036.
- Stemmer . Salomon M. . Manojlovic . Nebojsa S. . Marinca . Mihai Vasile . Petrov . Petar . Cherciu . Nelly . Ganea . Doina . Ciuleanu . Tudor Eliade . Pusca . Ioana Adriana . Beg . Muhammad Shaalan . Purcell . William T. . Croitoru . Adina-Emilia . Ilieva . Rumyana Nedyalkova . Natošević . Sladjana . Nita . Amedeia Lavinir . Kalev . Dimitar Nikolaev . Harpaz . Zivit . Farbstein . Motti . Silverman . Michael H. . Bristol . David . Itzhak . Inbal . Fishman . Pnina . Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial . Cancers . 7 January 2021 . 13 . 2 . 187 . 10.3390/cancers13020187 . 33430312 . 7825785 . 2072-6694 . free .
- Fishman . Pnina . Bareket-Samish . Avital . Itzhak . Inbal . Effects of namodenoson on pancreatic carcinoma: Preclinical evidence. . Journal of Clinical Oncology . 1 June 2023 . 41 . 16_suppl . e15134 . 10.1200/JCO.2023.41.16_suppl.e15134. 259081369 .
